

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

**TERMINATION OF
THE CONNECTED AND MAJOR TRANSACTION IN RELATION TO
SUBSCRIPTION OF SHARES INVOLVING ISSUE OF
CONSIDERATION SHARES UNDER SPECIFIC MANDATE**

References are made to the Company's announcements dated 4 May 2026, 2 July 2026 and 5 August 2026 (the "**Announcements**") in relation to the Subscription Agreement. Unless otherwise stated, capitalised terms used herein shall have the same meanings as defined in the Announcements.

Since the Company and IFGL contemplate that the conditions precedent to the Subscription Agreement (as more particularly set out in the section headed "Conditions Precedent" in the Company's announcement dated 4 May 2026) will not be fulfilled by the long stop date, i.e. 30 September 2026, the parties entered into a termination agreement on 17 September 2026 (the "**Termination Agreement**") to terminate the Subscription Agreement. With effect from the date of the Termination Agreement, each of the Company and IFGL has been released from all of their respective obligations, covenants and undertakings contained in the Subscription Agreement, and neither party thereto shall have any claim against the other for or on account of the Subscription Agreement or for or by reason of any act, matter or thing relating thereto.

As a result of the termination of the Subscription Agreement, the Subscription and the proposed issuance of the Consideration Shares will not proceed and therefore, no circular will be despatched to the Shareholders and the EGM will not be convened.

The Board considers that the termination of the Subscription Agreement will not have any material adverse effect on the operations of the Group.

By order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 17 September 2026

As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.